Approval · Notice of Compliance 32672 · 2024

REVLIMID: Notice of Compliance 32672

Issued February 9, 2024

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 32672
Date: February 9, 2024
Company: Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
REVLIMID	02459418	Marketed
REVLIMID	02304899	Marketed
REVLIMID	02304902	Marketed
REVLIMID	02317699	Marketed
REVLIMID	02440601	Marketed
REVLIMID	02317710	Marketed

Medicinal ingredients

LENALIDOMIDE 2.5 MG per CAP
LENALIDOMIDE 5 MG per CAP
LENALIDOMIDE 10 MG per CAP
LENALIDOMIDE 15 MG per CAP
LENALIDOMIDE 20 MG per CAP
LENALIDOMIDE 25 MG per CAP